title: Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
abstract: BACKGROUND
  Vedolizumab is the latest FDA-approved anti-integrin therapy for treatment of moderate-to-severe inflammatory bowel disease (IBD). The safety and efficacy of vedolizumab have been studied in short-term clinical trials.
  
  
  METHODS
  This paper reviews the safety profile of vedolizumab compared with other biologics. It also highlights the mechanism of action of the medication. We discuss the current position of vedolizumab in our current algorithm for IBD management and comment on future prospects of the drug.
  
  
  CONCLUSIONS
  Vedolizumab appears to be a safe and effective option in the treatment of moderate-to-severe IBD in the short term. Long-term observational studies and post-marketing safety data are needed to ascertain the long-term efficacy and side effect profile.
authors.affiliation: a 1 University of Maryland, Division of Gastroenterology and Hepatology, Department of Medicine , 100 North Greene Street, Lower Level, Baltimore, MD 21201, USA rcross@medicine.umaryland.edu.
authors.forename: Matilda
authors.initials: M
authors.lastname: Hagan
authors.forename: Raymond K
authors.initials: RK
authors.lastname: Cross
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000503:physiopathology; D003424:Crohn Disease / Q000188:drug therapy* / Q000503:physiopathology; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D012720:Severity of Illness Index
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; C543529:vedolizumab
keywords: Crohn’s disease; anti-adhesion molecule; anti-integrin; inflammatory bowel disease; natalizumab; ulcerative colitis; vedolizumab